Management of severe dyslipidaemia: Role of PCSK9 inhibitors

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulation of LDL receptors on the hepatocyte surface and therefore is essential for effective removal of LDL particles from circulation. Genetic and biochemical studies have established that altered PCSK9 functionality influences both LDL cholesterol levels and cardiovascular risk. This has prompted development of inhibitory strategies targeting PCSK9. Study of monoclonal PCSK9 antibodies has progressed to the clinic, where they have been found to lower LDL cholesterol levels and reduce cardiovascular event rates in large, clinical outcome trials. The use of PCSK9 inhibitors in the setting of dyslipidaemia is reviewed.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalEuropean Cardiology Review
Volume13
Issue number1
DOIs
Publication statusPublished - 1 Jun 2018
Externally publishedYes

Keywords

  • Atherosclerosis
  • Cardiovascular risk
  • Clinical trials
  • Lipids
  • Risk factors

Cite this